MediPal Holdings Corporation (MAHLY)
OTCMKTS
· Delayed Price · Currency is USD
14.60
-1.66 (-10.21%)
Jul 11, 2025, 4:00 PM EDT
MediPal Holdings Revenue
In the fiscal year ending March 31, 2025, MediPal Holdings had annual revenue of 3.67T JPY with 3.16% growth. MediPal Holdings had revenue of 864.16B in the quarter ending March 31, 2025, with 2.41% growth.
Revenue
3,671.33B JPY
Revenue Growth
+3.16%
P/S Ratio
0.14
Revenue / Employee
281.09M JPY
Employees
13,061
Market Cap
3.33B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 3,671.33B | 112.60B | 3.16% |
Mar 31, 2024 | 3,558.73B | 198.72B | 5.91% |
Mar 31, 2023 | 3,360.01B | 69.09B | 2.10% |
Mar 31, 2022 | 3,290.92B | 79.80B | 2.48% |
Mar 31, 2021 | 3,211.13B | -41.95B | -1.29% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |